Immune dysregulation fuels development of many diseases such as IBD, multiple sclerosis, rheumatoid arthritis, type 1 diabetes and asthma/allergy. Most of these diseases are frequent in developed nations, but much less common in less developed countries. The rapidly increasing incidence of these diseases in industrializing regions of the world suggests that environmental factors are inducing the spread of these conditions around the world.
ongoing inflammation. These models have helped to define the mechanisms of disease protection. It appears that helminth infections activate immune-regulatory circuits in their hosts and modulate the composition of intestinal flora, which appear to be the mechanisms of action. As there are many different helminth species living in different regions of their host, some of these species likely developed distinct approaches to modulate host immunity.
The following discussion reviews what has been learned regarding mechanisms through which helminthic control inflammation in IBD.
Space limitations do not allow a similar discussion for other conditions. However, pathways of regulation trend to echo among the various disease states and likely apply to effects on metabolism.
| REGULATORY DENDRITIC CELLS AND CONTROL OF MUCOSAL INFLAMMATION
In animal models of IBD, helminths induce regulatory dendritic cells One of the mechanisms of protection involves induction of regulatory DCs in the intestinal mucosa. 5 The process of induction does not require the interplay of T or B cells. DCs isolated from the intestines or mesentery lymph nodes (MLN) of Hpb-infected Rag mice and transferred into other uninfected Rag mice will render these animals resistant to colitis and impede intestinal mucosa production of colitogenic cytokines such as IFN-γ and IL-17. 6 This suggests that these DCs have an important role in protecting mice from the disease.
The regulatory DCs limit intestinal T-cell responses. Colitis prob-
ably results from inappropriate effector T-cell activation in the gut that drives the pathology. Through a cell contact-dependent mechanism, the regulatory DCs probably induce T-cell anergy preventing pro-inflammatory DCs from successfully activating the effector T cells that produce colitogenic cytokines. This regulatory process does not require Tregs, IL-10, TGF-β or IL-4. 6 However, these cells do not prevent effector T cells from populating the gut or MLN.
Hpb infection in the upper small bowel profoundly affects gene expression in DCs residing in distal regions of the gut. There is substantial downregulation of many components of the MHC antigenpresenting complex including CD80, CD86 and CD40. There also is reduced expression of several intracellular signalling pathways such as Jak1/2 and Syk, which drive production of proinflammatory cytokines that promote effector T-cell differentiation and activation.
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Hpb infection also diminishes the expression of many of the germ line-encoded pattern recognition receptors displayed on intestinal DCs. 7 These receptors, which include the Toll-like (Tlr) and C-type lectin (CLEC) receptors (CTLR) among others, bind molecular motifs on bacteria, fungi, viruses or stressed host cells. Ligation of these receptors triggers intracellular signalling that can determine whether
DCs will vigorously present antigen to effector T cells inducing their differentiation, proliferation and function, or perhaps render them inert.
Many of the CLECs induce phosphorylation of Syk to stimulate DC activation promoting adaptive immunity and strong Th1/Th17 responses. 8 Subsequent studies revealed that Hpb infection inhibited Syk expression in intestinal DCs, which proved to be a profoundly important observation.
Inactivation of Syk is a critical event that leads to the formation of regulatory DCs in the gut. Transgenic DCs with a block in Syk expression, harvested from mice with no prior worm infection, will block colitis if they are transferred into a colitic mouse. Hpb produces a molecule(s) that quickly and selectively inhibits DC Syk and CLEC expression suggesting that these parasites directly target this pathway. 15 Thus, induction of T-cell anergy could be one of the mechanisms through which these regulatory DCs inhibit T-cell responses that induce colitis.
Bone marrow-derived DCs pulsed with antigen from Hymenolepis diminuta and then transferred into mouse recipients will inhibit dinitrobenzene sulphonic acid (DNBS)-induced colitis. This protection by bone marrow-derived rather than gut or MLN-derived DCs appears to require animals that can express Th2 cytokines and IL-10. 16 
| THE IMPORTANCE OF REGULATORY T CELLS
In mice, Tregs in the gut produce IL-10, which helps to prevent aberrant intestinal inflammation. 17, 18 In the distal bowel of normal healthy mice, about 25% of the lamina propria CD4+ T cells express Foxp3, a marker of Tregs. 19, 20 These cells likely restrain the host immune response to the normal intestinal flora. Two highly studied murine models of IBD, the Rag IL-10−/− T-cell transfer model and the Rag/ CD25-CD4+ T-cell transfer model develop colitis because of Treg dysfunction. These models illustrate the importance of Tregs for maintenance of normal mucosal immune homoeostasis.
Heligmosomoides polygyrus bakeri (Hpb) infection expands the number of regulatory-type T cells that make IL-10 in the mesenteric lymph nodes (MLN) 21, 22 and intestinal lamina propria of its murine host.
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This helminth also "activates" Tregs making them highly regulatory. [24] [25] [26] In the CD25-CD4+ T-cell transfer model of IBD, the Foxp3+ IL-10+ CD4+ T-cell subset is essential for controlling the disease. Tregs. 32, 33 Helminths still prevent colitis in IL-10−/− mice 5, 21 in which the Tregs cannot make IL-10. The worm-induced, regulatory DCs (discussed above) also block colitis using mechanisms not dependent on Tregs and IL-10. Thus, there are at least two independent immuneregulatory networks driven by Hpb infection that limit the expression of colitis.
Helminths stimulate TGF-β production in the intestinal mucosa. (IL-17E) signalling resulted in worsened disease or increased disease progression in about 30% of patients given active agent as compared to 9% in those given placebo. 52 In mice, IL-17 responses are needed for effective host defence against intestinal pathogens such as
Citrobactor rodentium and Salmonella enterica serovar Typhimurium. 53 Mice exposed to Hpb have impaired resistance to enteric Citrobacter infection. 54 These findings show that balanced Th17 function is necessary for intestinal homoeostasis. Indeed, Th17 cells are diverse with subtypes promoting an inflammatory and others a regulatory skewed response. 55 Using reporter mice, we find that Hpb colonization alters intestinal Th17 plasticity, decreasing the proportion of inflammatory Th17/Th1 cells and increasing that of regulatory Th17/IL-10 cells (D.
E. Elliott, manuscript in preparation).
Another proinflammatory cytokine that has a complex role in intestinal homoeostasis is IL-6, which promotes Th17 differentiation and also is made by Th17 cells. Patients with Crohn's disease or ulcerative colitis have increased IL-6 production in their inflamed mucosa 56 suggesting that IL-6 drives intestinal inflammation. However, systemic blockade of IL-6 signalling with anti-IL-6R monoclonal antibody can induce intestinal ulceration 57 and exacerbated disease in a patient with ulcerative colitis. 58 IL-6 signalling inhibits intestinal epithelial cell death, and loss of this cytokine may amplify mucosal injury. 59 Lamina propria and mesenteric lymph node cells from mice exposed to Hpb produce more IL-6 compared to those cells from helminth-naïve mice.
IL-6 signals through its receptor to activate STAT3 promoting cell survival. 60 Intestinal epithelial cells from helminth-colonized mice display increased activated STAT3 expression which is dependent upon T-cell 
| INTERACTIONS BETWEEN HELMINTHS AND THE INTESTINAL MICROBIOTA HAVE A ROLE
Bacteria in the intestines readily interact with intestinal epithelium, mucosal DCs and other cells of the mucosal immune system. Hpb infection modifies the distribution and abundance of some intestinal bacteria. 61 There is an increase in Lactobacillaceae and Enterobacteriaceae species. 62, 63 There also is an increase in Lactobacillaceae family members during Trichuris muris infection. 64, 65 showed statistically significant disease improvement in patients given 2500 T. suis ova every 2 weeks for 12 weeks. 94 That study included a blinded crossover limb for patients with continued disease activity.
| CLINICAL TRIALS OF HELMINTHIC THERAPY FOR IMMUNE-MEDIATED DISEASE
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More patients who were initially on placebo improved when crossed over to T. suis (56.3%) than patients who were initially on T. suis and then switched to placebo (13.3%, P=.02). No adverse side effects were
recorded. An open-label study using T. suis (2500 ova every 3 weeks for 24 weeks) in patients with long-standing Crohn's also demonstrated safety and suggested efficacy with 72% achieving clinical remission.
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Two larger clinical trials using T. suis for active Crohn's disease focused on enrolling patients with early disease with the expectation it would be easier to influence the immune process in these test subjects compared to that of patients with long-established disease. However, those studies were plagued by very high placebo response rates that obscured any potential clinical effect. In addition, the parasite ova were prepared using different methodology and used at different dosages than that of the earlier studies which complicate interpretation of the results.
The European trial (Trust 2, NCT01279577) interim analysis suggested a dose-response with the lowest of the three doses used (250 ova) being ineffective. That low-dose limb was discontinued.
Enrolment criteria then were relaxed to hasten completion of trial. A high placebo rate occurred. The US study (Trust 1, NCT01279577) enrolled many patients with early disease that were mostly antiTNFa treatment unresponsive. This study also had an unexpectedly high placebo response rate. Both studies again confirmed the safety of T. suis in this patient population. However, the extraordinarily placebo rates of remission left the outcome of the studies indeterminate.
Coeliac disease is a common intestinal inflammation caused by delayed-type hypersensitivity to peptide antigens present in wheat, rye and barley gluten. Coeliac disease can cause abdominal discomfort, diarrhoea, skin rash, malnutrition, intestinal ulceration and intestinal lymphoma. Coeliac disease has been studied in clinical trials of N. americanus. 96, 97 Helminth exposure altered mucosal adaptive and innate immune responses, but there was no significant attenuation of a response to gluten. These studies used a gluten challenge of 16 g each day for 5 days which was clinically relevant, but immunologically quite aggressive. As little as 50 mg of gluten can reliably precipitate a response in patients with coeliac disease. 98 A second study to examine T. suis 2500 ova or placebo orally every 2 wks for 4 wks followed by 7500 ova every 2 wks for 12 wks, 4 week washout, then crossover 20 patients. Study terminated prior to enrollment.
Autism Double-blind placebocontrolled study NCT01734941
T. suis 2500 or 7500 ova or placebo orally every 2 wks for 16 wks 60 patients. Study terminated due to lack of available study agent
Please see text for relevant references.
T A B L E 1 (Continued) the diversity (operational taxonomic units) of the intestinal flora as compared to baseline challenge.
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Allergic rhinitis (AKA seasonal allergy, hay fever) is a common illness that has minimal morbidity, but has high socio-economic impact because it afflicts large numbers of people. Allergic rhinitis has been studied in clinical trials of T. suis 101 or N. americanus. 102 
Patients given
T. suis had less use of medications, but otherwise no change in symptoms. The timing of exposure to helminths in these studies was close to the seasonal onset of symptoms which may have limited their efficacy. The studies showed that medicinal exposure to either of these helminths was safe with minimal adverse effects.
102,103
Peanut allergy is an immediate-type (type 1) hypersensitivity response to oral peanut exposure. Patients with peanut allergy can develop itching, uticaria, vomiting/diarrhoea and severe potentially fatal anaphylaxis upon ingestion of even small amounts of antigen.
Peanut or tree nut allergy has been studied in an open-label clinical safety trial of T. suis. 104 The agent was well tolerated. Overall, they found no change in skin prick sensitivity except one patient lost reactivity to peanut allergen. Four patients reported improvement in seasonal allergy symptoms.
Asthma is a chronic remitting and relapsing inflammatory response that constricts the lung airways. Asthma exacerbations can cause wheezing, chest tightness, shortness of breath and death due to hypoxia. Asthma has been studied in a clinical trial using N. americanus. 105 Sixteen weeks after initial dermal exposure, there was a trend for decreased airway responsiveness to adenosine monophosphate challenge in patients exposed to helminths vs placebo which did not reach statistical significance. Other measures of asthma control were not changed but the exposure to a helminth which passes through the lung parenchyma was well tolerated in patients with underlying asthma.
Plaque psoriasis is a common chronic patchy skin rash usually involving the extensor surface areas of the limbs and back. It can be associated with arthritis and other organ involvement such as metabolic syndrome and heart disease. Psoriasis can cause severe itching, pain and secondary skin infections. Clinical trials of T. suis for plaque psoriasis have been initiated. One study (NCT01948271) was terminated due to lack of efficacy. The other studies were suspended due to lack of available study agent.
Rheumatoid arthritis is a chronic inflammation of the membranes occurs with higher frequency in families with multiple sclerosis than in that of the general population. Case studies suggest that patients with concurrent helminth infection had reduced severity of multiple sclerosis 106 and eradication of helminths exacerbated disease severity. 107 Multiple sclerosis has been studied in clinical trials of T. suis [108] [109] [110] [111] [112] For all clinical trials, it is important to clearly define the study population, primary and secondary endpoints, comparator therapy (eg placebo, best practices), treatment design, randomization/stratification process, oversight governance and data evaluation method. 115 Preclinical studies of helminth exposure in animal models of metabolic disease will help guide selection of the study population and study
endpoints. An initial important criterion will likely be central obesity. Treatment design will be constrained by the expected rapidity of response. T. suis began to influence ulcerative colitis disease severity (as measured by simple index) after 6 weeks of repeated exposure.
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To elicit change in components of the metabolic syndrome, it is likely that patients will need repeated inoculation over several months. If the endpoint condition is usually relatively stable over time, then this is achievable. However, if the condition waxes and wanes, then patient numbers may need to be increased to accommodate variance over time. The longer the study, the more difficult it is to enrol patients, the more patients become lost to follow-up and the more expensive the study becomes. Cumbersome treatment and testing procedures also negatively impact participation.
We did not find that use of helminths or "parasitic worms" deterred These purified products will also be amendable to clinical study but will need Phase 1 safety trials and may require more difficult treatment protocols if they need to be frequently injected.
| CONCLUSION
Animal models show that various helminth species prevent and/or block inflammation in various organs in a diverse range of diseases.
Many helminths use common approaches to accomplish this task. 
